SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
FLGT

Fulgent Genetics, Inc. (NASDAQ:FLGT)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$24.12-$0.66 (-2.66%)
 
Market cap
$674M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 29, 2016
Market Cap$673.89M-19.6%
Revenue (ttm)$330.27M+4.7%
Net Income-$90.93M-111.5%
EPS-$3.09-123.9%
Shares Out27.94M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume322,967
Open$24.73
Previous Close$24.78
Day's Range$23.92 - $24.73
52-Week Range$13.46 - $31.04
Beta1.00
AnalystsBuy
Price Target$19.00(-21.23%)
Earnings DateFeb 26, 2027

About FLGT

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.

Address
4978 Santa Anita Avenue, El Monte, CA, 91731, US
Market Cap
674 million
Employees
1,315
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$223.49K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
0 Buy1 Hold0 Sell

1 firm rating FLGT in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From FLGT’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.66%
5 Days
-1.43%
1 Month
+19.82%
6 Months
+38.78%
1 Year
-19.60%

$FLGT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in FLGT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by FLGT's directors and management

Net Shares Purchased by Insiders−6k−3k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

FLGT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

FLGT Revenue by Segment or Geography

FLGT's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New FLGT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to FLGT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in FLGT

IWMiShares Russell 2000 ETF$11.53M
VTIVanguard Morningstar Total Stock Market ETF$8.52M
DFASDimensional - US Small Cap ETF$4.89M
IWNiShares Russell 2000 Value ETF$4.14M
VXFVanguard Extended Market ETF$4.04M
FNDASchwab Fundamental U.S. Small Company Index ETF$3.49M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from FLGT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
51
News & Sentiment
20% of score
55

News check: Mixed coverage with technical analysis showing weakness, but company included in positive market growth reports; no major analyst actions or earnings catalysts present.

Recent Insider Activity

Buys
0
Sells
8
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-50.0 since Aug 29
0255075100Aug 29 — Insider Score 50.0Aug 30 — Insider Score 50.0Aug 31 — Insider Score 50.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 42.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 29Sep 16Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GERMETFMG Treatments, Testing and Advancements ETF1.68%
MYLDCambria ETF Trust - Cambria Micro and SmallCap Shareholder Yield ETF1.13%
NIFEDirexion Fallen Knives ETF0.92%
XHSState Street SPDR S&P Health Care Services ETF0.85%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF0.66%
EDOCGlobal X Telemedicine & Digital Health ETF0.47%
SBIOALPS Medical Breakthroughs ETF0.44%
GNOMGlobal X - Genomics & Biotechnology ETF0.39%
FVIFirst Trust Total US Market AlphaDEX ETF0.38%
APXHTwo Roads Shared Trust - APEX HealthCare ETF0.23%
DMRSDeltaShares S&P 600 Managed Risk ETF0.19%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.18%

Weight is the stock’s share of each fund’s holdings.